US: Endo settles FTC allegations that it paid rivals to delay generic competition
The Federal Trade Commission said Monday it had settled litigation that Endo International violated antitrust laws when it entered “anticompetitive reverse-payment” deals with rivals Watson Laboratories and Impax Laboratories to block lower-cost generic versions of Endo’s pain medicines.
The FTC charges were originally filed in US District Court in Philadelphia in March 2016, alleging that Endo used “pay for delay” agreements with Watson, now part of Allergan, and Impax to stay off the market with cheaper generic versions of Endo’s Opana ER, an opioid painkiller, and Lidoderm, a topical lidocaine patch, the FTC said.
Endo, with US headquarters in Malvern, said Monday it entered into a 10-year stipulated order with the FTC. Under the order, Endo will make no monetary payment, and the FTC will dismiss claims against the company. Endo will also not admit wrongdoing, the company said.
In the proposed settlement, the FTC sought an order barring the defendants from engaging in “similar anticompetitive behavior” in the future.
In the original lawsuit, the FTC alleged that “Endo knew that generic competition would decimate its sales of the corresponding branded product, and that any delay in generic competition would be highly profitable,” the agency said. “Faced with these threats to its lucrative drug franchises, Endo bought off its potential generic competitors.” Sales of Opana ER and Lidoderm were close to $1 billion in 2009, when the drugs were still on patent.
Full Content: Philly
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI